FAQ on Lantern Pharma's EU Patent for AI-Designed Cancer Drug LP-284

What is LP-284 and who developed it?

LP-284 is a clinical-stage drug candidate for relapsed or refractory non-Hodgkin’s lymphoma, developed by Lantern Pharma using its RADR(R) AI platform.

Why is the EU patent for LP-284 significant?

The EU patent adds to existing IP in the U.S. and Japan, supporting global commercialization efforts and ensuring exclusivity through 2039.

How does Lantern Pharma’s RADR(R) AI platform contribute to drug development?

The RADR(R) AI platform leverages over 200 billion oncology-focused data points and 200+ advanced ML algorithms to accelerate oncology drug discovery and development.

What are the Orphan Drug Designations for LP-284?

LP-284 holds Orphan Drug Designations for Mantle Cell Lymphoma (MCL) and High-Grade B-Cell Lymphoma (HGBL).

What is the global market target for LP-284?

LP-284 targets a $4 billion global market for relapsed or refractory non-Hodgkin’s lymphoma treatments.

How long does it take Lantern Pharma to advance a drug program to clinical trials?

On average, Lantern Pharma advances its drug programs from initial AI insights to first-in-human clinical trials in 2-3 years.

Where can I find more information about Lantern Pharma and LP-284?

More information is available in the company’s newsroom at https://ibn.fm/LTRN and the full press release at https://ibn.fm/Rx6Jq.

What is the cost efficiency of Lantern Pharma’s drug development programs?

Lantern Pharma’s drug development programs cost approximately $2.5 million per program from initial AI insights to first-in-human clinical trials.

Who can I contact for more information about BioMedWire?

For more information about BioMedWire, visit https://www.biomedwire.com or email Editor@BioMedWire.com.